Vecuronium is a nondepolarizing agent that achieves skeletal muscle paralysis by competing with acetylcholine for cholinergic receptor sites and binding with the nicotinic cholinergic receptor at the postjunctional membrane of the motor endplate. It is an aminosteroid neuromuscular blocking agent with intermediate duration of action when given intravenously, characterized by a rapid onset at intubating doses and recovery times suitable for elective surgical procedures. The drug produces neuromuscular blockade by reversible competitive antagonism of the nicotinic receptor without intrinsic agonist activity, and it has minimal direct cardiovascular stimulant effects compared with some older agents. Vecuronium is metabolized hepatically to an active 3-desacetyl metabolite and is eliminated via biliary and renal routes; clearance and duration are prolonged in significant hepatic impairment or in the presence of the active metabolite accumulation in renal insufficiency. Reversal of blockade is accomplished by acetylcholinesterase inhibitors such as neostigmine in combination with an antimuscarinic or by selective encapsulating agents that bind steroidal neuromuscular blockers.
Parent: Vecuronium
Parent: Vecuronium Bromide
Parent: Vecuronium
Parent: Vecuronium
Parent: Vecuronium
Typical quality control specifications for vecuronium active pharmaceutical ingredient and parenteral formulations target low levels of related substances with established limits for individual and total impurities. Known related compounds include 3-desacetyl-vecuronium, minor dealkylation and hydrolysis products, and trace quaternary degradation products. Common specification limits are: individual known impurity 3-desacetyl-vecuronium not greater than 0.20 percent by weight, any other individual related compound not greater than 0.10 percent, and total related substances not greater than 0.50 percent. Residual solvents are controlled to pharmacopeial limits, typically less than 0.5 percent for class 2 solvents when applicable, and heavy metals are controlled to trace limits consistent with ICH Q3D. Assay is routinely performed by validated reversed-phase HPLC with UV detection and related substances are quantified using gradient HPLC with appropriate standards and limits defined in the monograph or product specification.
Vecuronium is used to induce skeletal muscle relaxation and neuromuscular blockade during general anesthesia to facilitate endotracheal intubation and provide muscle relaxation for surgery or mechanical ventilation.
Vecuronium is a paralytic agent that causes neuromuscular blockade. It has no sedative or analgesic properties and must be used only in patients who are adequately anesthetized or sedated and monitored.
Vecuronium and rocuronium are both aminosteroid nondepolarizing neuromuscular blockers but they differ in onset, potency, and some pharmacokinetic properties. Rocuronium typically has a faster onset and is often used for rapid sequence induction, while vecuronium has an intermediate onset and a duration suited to routine surgical procedures. Both can be reversed by selective binding agents for steroidal blockers.
Yes, vecuronium is considered a high risk medication because inappropriate use can cause prolonged paralysis and respiratory arrest. It requires administration by trained clinicians, continuous monitoring of ventilation and neuromuscular function, and procedures for immediate reversal and airway management.
